"alpha-Galactosidase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An enzyme that catalyzes the hydrolysis of terminal, non-reducing alpha-D-galactose residues in alpha-galactosides including galactose oligosaccharides, galactomannans, and galactolipids.
| Descriptor ID |
D000519
|
| MeSH Number(s) |
D08.811.277.450.410.050
|
| Concept/Terms |
alpha-Galactosidase- alpha-Galactosidase
- alpha Galactosidase
- alpha-Galactosidases
- alpha Galactosidases
- Melibiase
- alpha-Galactosidase A
- alpha Galactosidase A
|
Below are MeSH descriptors whose meaning is more general than "alpha-Galactosidase".
Below are MeSH descriptors whose meaning is more specific than "alpha-Galactosidase".
This graph shows the total number of publications written about "alpha-Galactosidase" by people in this website by year, and whether "alpha-Galactosidase" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2016 | 0 | 1 | 1 |
| 2017 | 4 | 1 | 5 |
| 2018 | 9 | 6 | 15 |
| 2019 | 2 | 2 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "alpha-Galactosidase" by people in Profiles.
-
Fabry disease during the COVID-19 pandemic. Why and how treatment should be continued. Mol Genet Metab. 2020 08; 130(4):227-229.
-
Identifying Fabry patients in dialysis population: prevalence of GLA mutations by renal clinic screening, 1995-2019. J Nephrol. 2020 Jun; 33(3):569-581.
-
What rheumatologist should know about Fabry disease. Ann Rheum Dis. 2020 06; 79(6):e71.
-
Fabry's disease and stroke: Effectiveness of enzyme replacement therapy (ERT) in stroke prevention, a review with meta-analysis. J Clin Neurosci. 2019 Jul; 65:83-86.
-
Searching for an additional treatment to slowing the progression of Fabry disease. Minerva Med. 2019 Apr; 110(2):176-178.
-
Identification of a novel loss-of-function mutation of the GLA gene in a Chinese Han family with Fabry disease. BMC Med Genet. 2018 12 27; 19(1):219.
-
Computational and modeling approaches to understand the impact of the Fabry's disease causing mutation (D92Y) on the interaction with pharmacological chaperone 1-deoxygalactonojirimycin (DGJ). Adv Protein Chem Struct Biol. 2019; 114:341-407.
-
Mutations in the GLA Gene and LysoGb3: Is It Really Anderson-Fabry Disease? Int J Mol Sci. 2018 Nov 23; 19(12).
-
Oxidative stress and the altered reaction to it in Fabry disease: A possible target for cardiovascular-renal remodeling? PLoS One. 2018; 13(9):e0204618.
-
The effect of enzyme replacement therapy on clinical outcomes in female patients with Fabry disease - A systematic literature review by a European panel of experts. Mol Genet Metab. 2019 03; 126(3):224-235.